Skip to main content

Drug Interactions between Azstarys and phenylbutazone

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

phenylbutazone dexmethylphenidate

Applies to: phenylbutazone and Azstarys (dexmethylphenidate / serdexmethylphenidate)

MONITOR: The coadministration with methylphenidate may increase the plasma concentrations of phenylbutazone. According to the manufacturer, human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of phenylbutazone.

MANAGEMENT: Pharmacologic response to phenylbutazone should be monitored more closely whenever methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) is added to or withdrawn from therapy, and the phenylbutazone dosage adjusted as necessary.

References (1)
  1. (2001) "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals
Moderate

phenylbutazone serdexmethylphenidate

Applies to: phenylbutazone and Azstarys (dexmethylphenidate / serdexmethylphenidate)

MONITOR: The coadministration with methylphenidate may increase the plasma concentrations of phenylbutazone. According to the manufacturer, human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of phenylbutazone.

MANAGEMENT: Pharmacologic response to phenylbutazone should be monitored more closely whenever methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) is added to or withdrawn from therapy, and the phenylbutazone dosage adjusted as necessary.

References (1)
  1. (2001) "Product Information. Ritalin (methylphenidate)." Novartis Pharmaceuticals
Moderate

dexmethylphenidate serdexmethylphenidate

Applies to: Azstarys (dexmethylphenidate / serdexmethylphenidate) and Azstarys (dexmethylphenidate / serdexmethylphenidate)

MONITOR: Coadministration of two or more sympathomimetic agents may increase the risk of adverse effects such as nervousness, irritability, and increased heart rate. Central nervous system (CNS) stimulants, particularly amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.

MANAGEMENT: Caution is advised if two or more sympathomimetic agents are coadministered. Pulse and blood pressure should be closely monitored.

References (7)
  1. Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr (1979) "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res, 1, p. 45-52
  2. Cavanaugh JH, Griffith JD, Oates JA (1970) "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther, 11, p. 656
  3. (2001) "Product Information. Adderall (amphetamine-dextroamphetamine)." Shire Richwood Pharmaceutical Company Inc
  4. (2001) "Product Information. Tenuate (diethylpropion)." Aventis Pharmaceuticals
  5. (2001) "Product Information. Sanorex (mazindol)." Novartis Pharmaceuticals
  6. (2001) "Product Information. Focalin (dexmethylphenidate)." Mikart Inc
  7. (2002) "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer